In part 9, we discussed the commercial foundation and infrastructure that determine whether a CGT launch has a chance to succeed on its own operational terms. Those internal investments, however, ultimately have to survive contact with the audiences judging it from the outside: investors, analysts, media, and the broader biopharma community. Left to their own devices, those audiences will apply frameworks borrowed from conventional launches, which fit CGTs poorly and produce misleadingly negative readings of what is actually happening. The stakes are highest for a first launch and for smaller companies, which have no broader portfolio or track record to absorb market nerves.

In this final installment (for now!), we focus on external communications and why controlling the launch narrative is one of the most consequential and most under-managed dimensions of CGT commercialization.

Set the Frame Before the Market Sets It for You

CGT launches rarely follow conventional trajectories. Early uptake is typically constrained by site readiness, payer negotiations, and operational throughput rather than by lack of clinical interest, which means the first several quarters of revenue often understate real demand. This dynamic is well understood inside the manufacturer but rarely understood outside it. That gap is where the trouble starts.

Absent a deliberate external narrative, investors and analysts will default to the metrics they know: quarterly revenue, script equivalents, and market share benchmarks against conventional specialty comparators. Those frameworks are largely irrelevant to the first year or two of a CGT launch and applying them produces a story of underperformance that has little to do with whether the launch is on track. Between patient identification and revenue recognition sit referral, screening, apheresis scheduling, reimbursement approval, and manufacturing, and that gap can run several months. Setting that expectation before launch is far easier than explaining it afterward. The window to set a different frame, however, closes quickly. By the second or third earnings call, whatever narrative has taken hold in the analyst community becomes the reference point against which everything else is measured.

Manufacturers that get this right start setting the frame well before launch. Pre-launch communications should focus on establishing credibility in the underlying technology and confidence in the operational readiness behind it: what the platform is, why it works, what the manufacturing and delivery infrastructure looks like, which authorized treatment centers (ATCs) are being activated, and what a realistic ramp looks like for a therapy of this type*.

That last point is critical. A market that hears “the ramp will be slower, and here is why” from the manufacturer six months before launch perceives that ramp very differently than a market that discovers it in the first quarterly miss. Concrete milestones carry that message better than narrative alone, e.g., naming a value chain partner, standing up the lead ATCs, and completing the legal agreements required to treat the first patient. When audiences cannot yet see results, what reassures them is evidence of a plan.

Post-Launch: Shift the Story to Execution and Coverage

Once the therapy is on the market, the external story has to evolve. Pre-launch communications established confidence in the science and the infrastructure. Post-launch communications must demonstrate execution. It’s imperative to show that the machinery is running, the funnel is moving, and the operational and access foundations are converting into treated patients.

The leading indicators most worth elevating in external communications:

  • Site activations and the pace of ATC network expansion
  • Patient referral volume trends and intake initiations
  • Coverage decisions and payer policy wins across national and regional plans, reported at least directionally when specifics are confidential
  • Apheresis and infusion volume growth, where product-appropriate
  • Real-world outcomes and long-term follow-up milestones, connecting back to the evidence agenda discussed in part 5

These metrics do two things at once:

  • Give external audiences a credible way to assess launch health that is not distorted by the timing lag between activation and revenue
  • Signal that the manufacturer has a sophisticated understanding of what actually drives success in this modality

Analysts handed a coherent leading-indicator framework tend to use it. Analysts left to invent one often reach for the wrong tools.

Anticipate the Slower Ramp and Give It a Narrative

The single most predictable feature of a CGT launch is that early revenue will look modest relative to expectations built on conventional specialty benchmarks. This is the direct consequence of small eligible populations, complex logistics, multi-month patient journeys, and the payer, site, and operational constraints we have discussed throughout this series. Manufacturers that anticipate this reality and give it an explicit narrative are much better positioned to protect confidence during the ramp.

The problem often begins with the forecast itself, which is frequently built on conventional assumptions that very few, if any, CGT launches can support. Aligning realistic internal and external forecast assumptions well before launch keeps a company’s own guidance from setting an expectation its operations cannot meet. Explaining the shape of the ramp, and the factors that determine its slope, gives investors a framework for interpreting what they see each quarter. Indication sequencing helps here too. A first approval in a small population reads differently when it is framed as the opening step in a deliberate expansion plan rather than as the whole opportunity.

Highlighting the leading indicators that move before revenue does redirects attention from the one trailing metric that is least informative in year one. And being candid about which constraints are transient, which are structural, and what is being done about each builds confidence in both the therapy and the team behind it. Without that discipline, a manufacturer can find itself in a familiar cycle: an optimistic pre-launch narrative meets an inevitably slower ramp, quarterly misses accumulate, analyst confidence erodes, and the company spends the next several quarters trying to reset expectations from a defensive posture.

The Bottom Line

External communications are how everything else in this series – education, ATC readiness, referral pathways, reimbursement, evidence generation, patient engagement, patient support, internal training, and commercial infrastructure – is interpreted by the outside world. Manufacturers that control the launch narrative by establishing leading indicators early, shifting the story from science to execution at launch, and giving the slower CGT ramp an honest and coherent framing, are the ones whose launches are judged on the right terms. Those that leave the narrative to the market tend to spend the first two years explaining why the wrong metrics don’t apply. The old political adage applies: if you’re explaining, you’re losing.

Across all ten factors in this series, the underlying pattern is consistent: CGT commercialization rewards manufacturers who recognize that these therapies do not fit the conventional biopharma playbook and who invest proactively in the capabilities the modality requires. It is harder than a conventional launch. Done well, it is also among the most consequential things a commercial organization can do.

 

*In markets with near-term competition, some supporting go-to-market details are better kept confidential.